PHAT
NASDAQ
US
Phathom Pharmaceuticals, Inc. - Common Stock
$11.34
▲ +$0.20
(+1.80%)
Vol 786K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.2B
ROE
-232.8%
Margin
-186.5%
D/E
1238.07
Beta
0.48
52W
$2–$18
Wall Street Consensus
17 analysts · Apr 20266
Strong Buy
9
Buy
2
Hold
0
Sell
0
Strong Sell
88.2%
Buy Rating
Price Chart
Similar Stocks
COLL
Collegium Pharmaceutical Inc
P/E 25.0
$1.5B
XERS
Xeris Biopharma Holdings Inc
$1.3B
AMPH
Amphastar Pharmaceuticals Inc
P/E 11.0
$1.2B
PCRX
Pacira Biosciences Inc
P/E 51.9
$1.1B
BIOA
BIOAGE Labs Inc
$474.4M
OMER
Omeros Corp
$1.2B
SGP
SpyGlass Pharma Inc
RLMD
Relmada Therapeutics Inc
$354.2M
ARVN
Arvinas Inc
$761.7M
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.39 | $-0.29 | +$0.10 |
| Sep 2025 | $-0.56 | $-0.41 | +$0.15 |
| Jun 2025 | $-1.06 | $-1.05 | +$0.01 |
| Mar 2025 | $-1.17 | $-1.31 | $-0.14 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -232.8% | -232.8% | -232.8% | -232.8% | -232.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -191.9% | -289.5% | -289.5% | -186.5% | -186.5% | -186.5% |
| Gross Margin | 87.2% | 86.9% | 86.9% | 87.2% | 87.2% | 87.2% |
| D/E Ratio | — | 1238.07 | 1238.07 | 1238.07 | 1238.07 | 1238.07 |
| Current Ratio | 2.38 | 2.38 | 2.38 | 2.23 | 2.23 | 2.23 |
Key Ratios
ROA (TTM)
-94.4%
P/S (TTM)
8.02
P/B
8.3
EPS (TTM)
$-3.81
CF/Share
$-3.74
52W High
$18.31
52W Low
$2.21
$2.21
52-Week Range
$18.31
How does PHAT compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
PHAT valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
8.0
▲
62%
above
peers
(5.0)
vs Peers
vs Industry
Pricier
P/B ratio
8.3
▲
293%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
PHAT profitability vs Pharmaceuticals peers
ROE
-232.8%
▼
329%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
-186.5%
▼
294%
below
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
87.3%
▲
28%
above
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-94.4%
▼
152%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
PHAT financial health vs Pharmaceuticals peers
D/E ratio
1238.1
▲
80294%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
2.2
▼
34%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
0.5
▼
49%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
PHAT fundamentals radar
PHAT
Peer median
Industry
PHAT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
PHAT vs peers: key metrics
Latest News
An Alphatec VP Sold Company Shares Worth $1.4 Million. Should Investors Avoid …
Nasdaq · Mar 28
Is Alphatec Holdings, Inc. (ATEC) A Good Stock To Buy Now?
Yahoo Finance · Mar 21
AlphaTON Buys 60% Stake In Web3 Gaming Platform GAMEE
Yahoo Finance · Mar 21
First Phosphate secures $16.7M in federal funding for Québec phosphate project
Yahoo Finance · Mar 17